Shares are trading at $2.32 barely above the 50 day moving average of $2.19 and which is quite a bit above the 200 day moving average of $1.91. The 50 day moving average moved up $0.13 and the 200 day average went up by +21.70%. Kitov Pharmaceuticals Holdings shares had a trading volume of 256K on Tuesday. Trading volume was down 72.22% under the stocks average daily volume.
Short traders are feeling a little more bearish on Kitov Pharmaceuticals Holdings as evidenced by the increase in short interest. The stock had a rise in short interest between September 29, 2017 and October 13, 2017 of 49.49%. Short interest increased 159,530 over that timeframe. The short-interest ratio decreased to 0.0 and the percentage of shorted shares is 0.06% as of October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (KTOV). As of the end of the quarter Menta Capital LLC had disposed of 2,800 shares trimming its position 3.7%. The value of the total investment in Kitov Pharmaceuticals Holdings decreased from $145,000 to $111,000 a change of 23.4% quarter to quarter. As of quarter end Kcg Holdings, Inc. had sold a total of 7,373 shares trimming its stake by 34.6%. The value of the investment in KTOV went from $41,000 to $21,000 a change of $20,000 quarter over quarter.
Psagot Investment House Ltd. grew its investment by buying 34,489 shares an increase of 12,679.8% as of 06/30/2017. Psagot Investment House Ltd. now holds 34,761 shares worth $53,000. The value of the position overall is up by 5,200.0%. Ubs Group Ag divested its position by selling 3,546 shares a decrease of 46.9%. Ubs Group Ag now controls 4,014 shares valued at $6,000. The total value of its holdings decreased 60.0%.
Kitov Pharmaceuticals Holdings Ltd., through its subsidiary, Kitov Pharmaceuticals Ltd., operates as a clinical development stage biopharmaceutical company. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company’s lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study. It is also developing KIT-301, which is based on the generic drugs naproxen and isradipine. . The company was formerly known as Mainrom Line Logistics Ltd. and changed its name to Kitov Pharmaceuticals Holdings Ltd. in August 2013. Kitov Pharmaceuticals Holdings Ltd. was incorporated in 1968 is based in Tel Aviv, Israel..